<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02613559</url>
  </required_header>
  <id_info>
    <org_study_id>Tmab-TK001-AMD-01</org_study_id>
    <nct_id>NCT02613559</nct_id>
  </id_info>
  <brief_title>Evaluation the Pharmacokinetics, Safety, Tolerability of TK001 in Patients With Neovascular Age-related Macular Degeneration</brief_title>
  <official_title>A Single-center, Open-label, Single Ascending Dose Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Tolerability of Intravitreal TK001(Recombinant Humanized Anti-VEGF Monoclonal Antibody) in Subjects With Neovascular Age-Related Macular Degeneration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu T-Mab Biopharma Co.,Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu T-Mab Biopharma Co.,Ltd</source>
  <brief_summary>
    <textblock>
      The purpose of this first-in-human study is to evaluate the safety, pharmacokinetics and&#xD;
      tolerability of single ascending doses of TK001(Recombinant humanized anti-VEGF monoclonal&#xD;
      antibody) to determine the maximum tolerated dose (MTD) in neovascular wet age-related&#xD;
      macular degeneration (wAMD) subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, non-comparative, non-randomized, single-center phase 1 study&#xD;
      evaluating pharmacokinetics, safety and tolerability of single intravitreal injections of&#xD;
      TK001 in the patients with AMD.TK001 is a full-length recombinant humanized anti-VEGF&#xD;
      monoclonal antibody. Compared with Avastin(a similar marketed product), the findings of&#xD;
      preclinical studies suggested that TK001 might be more effective in inhibiting pathological&#xD;
      angiogenesis, or to achieve equivalent effect with less dosage and better safety. In this&#xD;
      study, participants will be administrated a single dose of TK001.Every subject will only&#xD;
      accept one dose. In addition to safety and preliminary efficacy, pharmacokinetics and&#xD;
      immunogenicity of TK001will be evaluated as well.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2015</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of ocular and systemic AEs (adverse events) and SAEs (serious adverse events) which are related to TK001</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Best Corrected Visual Acuity (BCVA)</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve from time zero to infinity (AUCinf)</measure>
    <time_frame>Up to Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve from time zero to time 't' where t is a defined time point after administration (AUC0-t)</measure>
    <time_frame>Up to Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed maximum plasma concentration (Cmax)</measure>
    <time_frame>Up to Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach the maximum observed plasma concentration (Tmax)</measure>
    <time_frame>Up to Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of subjects with anti-TK001 antibody</measure>
    <time_frame>Up to Day 42</time_frame>
    <description>Anti- TK001 antibody will be detected pre-dose,14d and 42d.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">27</enrollment>
  <condition>Neovascular Age-related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>TK001 0.1mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Injection:single Intravitreal Injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TK001 0.5mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Injection:single Intravitreal Injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TK001 1.0mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Injection:single Intravitreal Injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TK001 2.0mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Biological: TK001 Injection:single Intravitreal Injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TK001 2.5mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Biological: TK001 Injection:single Intravitreal Injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TK001 3.0mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Injection:single Intravitreal Injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>TK001</intervention_name>
    <description>Intravitreal Injection</description>
    <arm_group_label>TK001 0.1mg</arm_group_label>
    <arm_group_label>TK001 0.5mg</arm_group_label>
    <arm_group_label>TK001 1.0mg</arm_group_label>
    <arm_group_label>TK001 2.0mg</arm_group_label>
    <arm_group_label>TK001 2.5mg</arm_group_label>
    <arm_group_label>TK001 3.0mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients or their legal representative signed informed consent&#xD;
&#xD;
          -  Aged 45 years to 80 years, male or female&#xD;
&#xD;
          -  Inpatient/Outpatient with confirmed neovascular AMD&#xD;
&#xD;
          -  Best corrected VA for the studied eye≤20/100&#xD;
&#xD;
          -  With primary or recurrent subfoveal choroidal neovascular (CNV) lesions secondary to&#xD;
             neovascular AMD&#xD;
&#xD;
          -  Blood pressure is stable with SBP&lt;140 mmHg and DBP&lt;90 mmHg with or without treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Limitation of eye diseases&#xD;
&#xD;
               1. The studied eye suffered intravitreal blood within two months prior to screening&#xD;
&#xD;
               2. The studied eye suffered structural damage of retinal which involved macular&#xD;
                  center(such as epiretinal membrane, scars, laser burns, foveal atrophy, dense&#xD;
                  pigment changes, intensive subfoveal hard exudates)&#xD;
&#xD;
               3. Apparent cataract, aphakia, pseudoexfoliation syndrome, intraocular hemorrhage&#xD;
                  resulting in decreased vision, rhegmatogenous retinal detachment, macular hole,&#xD;
                  diabetic retinopathy and diabetic macular disease which need to be treated,&#xD;
                  choroidal neovascularization (CNV) for any reason except for AMD (such as ocular&#xD;
                  histoplasmosis, pathologic myopia)&#xD;
&#xD;
               4. Afferent pupillary defect(APD)&#xD;
&#xD;
               5. Refractive media opacity and miosis which effect fundus examination&#xD;
&#xD;
               6. Any eye of patient with active inflammation, such as conjunctivitis, keratitis,&#xD;
                  scleritis, uveitis and endophthalmitis&#xD;
&#xD;
               7. Choroidal neovascularization (CNV) for other reason, such as diabetic&#xD;
                  retinopathy, fundus angioid streaks, ocular histoplasmosis, pathologic myopia,&#xD;
                  trauma&#xD;
&#xD;
          -  The treatment of the eye&#xD;
&#xD;
               1. The studied eye received topical or grid photocoagulation more than twice or&#xD;
                  within 3 months before screening&#xD;
&#xD;
               2. The studied eye received any intraocular surgery or laser treatment (such as&#xD;
                  macular translocation surgery, glaucoma filtering surgery, verteporfin&#xD;
                  photodynamic therapy, transpupillary thermotherapy, foveal photocoagulation&#xD;
                  surgery, cataract surgery, vitreous cutting surgery, optic nerve incision&#xD;
                  operation, YAG posterior capsular incision surgery, sheath incision surgery or&#xD;
                  filtering surgery) within 3 months before screening&#xD;
&#xD;
               3. Any eye received antiangiogenic drugs (including any anti-VEGF drugs) (such as&#xD;
                  pegaptanib [Macugen®], Aflibercept [Eylea®], ranibizumab [Lucentis ®],&#xD;
                  bevacizumab [Avastin ®]) within 3 months before baseline visit&#xD;
&#xD;
               4. Any eye received intraocular injection of corticosteroid drugs (such as&#xD;
                  triamcinolone acetonide), or periocular injection of corticosteroid drugs within&#xD;
                  1 months before screening&#xD;
&#xD;
          -  Systemic diseases,treatment and other conditions&#xD;
&#xD;
               1. With a history of allergy to sodium fluorescein and indocyanine green&#xD;
&#xD;
               2. PLT≤100×109/L, BUN, Cr, thrombin time and prothrombin time beyond the upper limit&#xD;
                  of the normal range; take anti-platelet aggregation drugs within a month prior to&#xD;
                  enrollment&#xD;
&#xD;
               3. With surgery within one month prior to enrollment, or with unhealing wound,&#xD;
                  ulcer, fracture at present&#xD;
&#xD;
               4. Diabetic patients without the control of glucose or accompanied by diabetic&#xD;
                  retinopathy&#xD;
&#xD;
               5. With a history of myocardial infarction within 6 months before enrolled&#xD;
&#xD;
               6. With activity disseminated intravascular coagulation and a tendency of&#xD;
                  significant bleeding prior to enrollment&#xD;
&#xD;
               7. Systemic autoimmune disease&#xD;
&#xD;
               8. Any uncontrolled clinical problems (such as severe systemic diseases of mental,&#xD;
                  neurological, cardiovascular, respiratory and malignancies)&#xD;
&#xD;
               9. Pregnant and lactating women and patients who cannot take contraceptive measures&#xD;
&#xD;
              10. Poor compliance&#xD;
&#xD;
              11. The patients who is considered unsuitable for enrollment by investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ming Zhang</last_name>
    <role>Principal Investigator</role>
    <affiliation>West China Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Guangfu Li</last_name>
    <email>guangfuli@t-mab.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>West China Hospital, Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ming Zhang</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <study_first_submitted>November 21, 2015</study_first_submitted>
  <study_first_submitted_qc>November 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 24, 2015</study_first_posted>
  <last_update_submitted>February 27, 2018</last_update_submitted>
  <last_update_submitted_qc>February 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neovascular Age-Related Macular Degeneration, Subfoveal CNV, TK001</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Wet Macular Degeneration</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

